USFDA cheer for Sun Pharma & Cipla
DSIJ Intelligence / 16 Feb 2017
In a cheer for pharmaceuticals major Sun Pharmaceuticals and Cipla, United States Food & Drugs Administration (USFDA) has approved one drug each from both the generic drug major.
In a cheer for pharmaceuticals major Sun Pharmaceuticals and Cipla, United States Food & Drugs Administration (USFDA) has approved one drug each from both the generic drug major.
Sun Pharmaceuticals received tentative USFDA nod for Tadalafil tablets. The drug is a generic version of Pfizer’s blockbuster drug Viagra which went generic few years back. Tadalafil tablets relaxes muscles found in the walls of blood vessels and increases blood flow in various parts of the body.
On the hand, Cipla got regulatory go ahead for Oxaliplatin Injectable. Oxaliplatin is a chemotherapy drug based on platinum. It is used to treat bowel cancer (colorectal cancer), food pipe cancer (oesophageal cancer) and stomach cancer.
Reacting to the news, Sun Pharma & Cipla were trading higher with gains of 2.02 and 1.10 per cent.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.